Management of Chronic Constipation

Introduction and Diagnosis

Chronic constipation can be managed with magnesium citrate 250mg twice daily as an osmotic laxative, though it may also be used for magnesium supplementation in patients with hypomagnesuria or kidney stone prevention, as recommended by the American Gastroenterological Association (AGA) and American College of Gastroenterology (ACG) guidelines 1
Standard starting dose of magnesium citrate is 400-500mg daily, which can be titrated based on symptom response and side effects, with clinical practice often using 250-500mg BID 1

Magnesium-based products, such as magnesium citrate, are effective treatments for chronic idiopathic constipation, increasing bowel movements (CSBMs by 4.29 per week compared to placebo) and improving stool consistency and quality of life, with a low cost (<$50 monthly) 1
Polyethylene glycol (PEG) is recommended as the first-line treatment for constipation in CKD stage 4 patients, with an initial dose of 17g daily mixed in water, and has advantages including no significant systemic absorption, safety in CKD, and durability of effect for up to 6 months, as recommended by the American Gastroenterological Association with moderate certainty and strong evidence 1
Psyllium fiber supplements can be used alone or with PEG, with an initial dose of 14g/1,000 kcal intake per day, and require adequate hydration to prevent worsening constipation 1
Lactulose is the only osmotic agent specifically studied in pregnancy and should be preferred (15g daily) 1
Stimulant laxatives (senna 8.6-17.2mg daily) may be used for short-term relief in pregnant patients, while bisacodyl should be avoided for long-term use due to limited safety data 1
Prescription medications (linaclotide, plecanatide, lubiprostone, or prucalopride) can be considered for refractory cases in patients with neurological conditions or other complex cases 1, 2

Increasing fluid intake as tolerated within fluid restrictions, increasing dietary fiber intake (aiming for >10g/day) if tolerated, and encouraging physical activity as appropriate can help manage constipation in CKD stage 4 patients 1, 3, 4
Increase dietary fiber (aim for 14g/1000 kcal) and fluid intake to help manage chronic constipation in pregnant patients 1
Consider using fermented milk containing probiotics and prebiotic fiber to help manage constipation, particularly in neurological conditions 4
Fractionating meals may be considered in patients with muscular fatigue to help manage constipation 4

Renal insufficiency/kidney disease is a high-risk condition for hypermagnesemia, and magnesium citrate should be used with caution in patients with diabetes, as they may have poorer response to bowel preparations 1, 5
Magnesium oxide and other magnesium-containing laxatives are contraindicated in CKD stage 4 due to the high risk of hypermagnesemia, but can be used with caution (400-500mg daily) in patients with chronic constipation without renal insufficiency 1, 3

Assessing response to treatment and adjusting as needed, monitoring for electrolyte abnormalities, particularly with osmotic laxatives, and discontinuing any non-essential constipating medications are important aspects of constipation management in CKD stage 4 patients 3, 6, 1
Rule out impaction or mechanical obstruction before escalating therapy, and assess for other causes of constipation (hypercalcemia, hypokalemia, hypothyroidism, diabetes mellitus, medication side effects) 3, 6

PEG (17g daily) is particularly effective in older adults with fewer side effects 1
Osmotic laxatives (lactulose or magnesium oxide) can be used in older adults, but magnesium should be avoided in renal insufficiency 1
Stimulant laxatives (bisacodyl 5mg daily or senna) can be used for short-term use or rescue therapy in older adults 1
Prucalopride has a strong recommendation for use in neurological conditions 1
Polyethylene glycol (PEG) can be used as first-line pharmacological treatment, combined with psyllium fiber supplements for enhanced effect, in patients with multiple sclerosis (MS) or other neurological disorders 1